DalsnaFinance

Fennec Pharmaceuticals Inc $FENC

Health Care

Russell 2000 North Carolina
Create a scorecard
$10.32
-0.06 (-0.58%)
As of Oct 22, 2026, 9:31 PM EDT
Price history
Loading chart…

Fennec Pharmaceuticals Inc (FENC) is trading down at $10.32 (-0.58%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.

Fennec Pharmaceuticals Inc revenue & net income history (FY2016–FY2025)

RevenueNet incomeNet margin (right axis, %)
$47.5M$11.9M−$23.7MFY2016 revenue: $0FY2016 net income: −$2.79M'16FY2017 revenue: $0FY2017 net income: −$7.05M'17FY2018 revenue: $0FY2018 net income: −$9.89M'18FY2019 revenue: $0FY2019 net income: −$12.8M'19FY2020 revenue: $170.0KFY2020 net income: −$18.1M · Net margin −10652.4%'20FY2021 net income: −$17.3M'21FY2022 revenue: $1.53MFY2022 net income: −$23.7M · Net margin −1544.9%'22FY2023 revenue: $21.3MFY2023 net income: −$16.0M · Net margin −75.5%'23FY2024 revenue: $47.5MFY2024 net income: −$436.0K · Net margin −0.9%'24FY2025 revenue: $44.6MFY2025 net income: −$9.74M · Net margin −21.8%'25−50%0%50%FY2020 net margin: −10652.4% (off the scale, which stops at −62.4%)FY2022 net margin: −1544.9% (off the scale, which stops at −62.4%)FY2023 net margin: −75.5% (off the scale, which stops at −62.4%)FY2024 net margin: −0.9%FY2025 net margin: −21.8%
Fennec Pharmaceuticals Inc annual financial statements
FY2016Dec 2016FY2017Dec 2017FY2018Dec 2018FY2019Dec 2019FY2020Dec 2020FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Revenue$0$0$0$0$170.0K—$1.53M$21.3M$47.5M$44.6M
Growth (year over year)———————+1284.5%+123.7%−6.1%
Gross profit——————$1.45M$20.0M——
Gross margin——————94.4%94.1%——
Operating income−$2.87M−$6.95M−$10.4M−$13.0M−$17.9M−$17.2M−$22.6M−$12.8M$2.57M−$6.28M
Operating margin————−10520.6%—−1471.6%−60.1%5.4%−14.1%
Net income−$2.79M−$7.05M−$9.89M−$12.8M−$18.1M−$17.3M−$23.7M−$16.0M−$436.0K−$9.74M
Net margin————−10652.4%—−1544.9%−75.5%−0.9%−21.8%
EPS (diluted)−$0.22−$0.47−$0.52−$0.64−$0.76−$0.67−$0.90−$0.60−$0.02−$0.34
Balance sheet
Cash and equivalents$3.93M$28.3M$22.8M$13.7M$30.3M$21.1M$23.8M$13.3M$26.6M$36.8M
Total assets$3.97M$28.4M$22.9M$14.1M$31.4M$22.4M$26.9M$26.9M$44.9M$70.6M
Total liabilities$402.0K$1.64M$1.64M$2.27M$2.35M$6.64M$29.5M$38.5M$50.8M$35.1M
Long-term debt—————$5.00M$24.9M$30.9M$19.3M—
Shareholders' equity$3.57M$26.8M$21.3M$11.9M$29.1M$15.8M−$2.57M−$11.6M−$5.87M$35.5M
Cash flow
Operating cash flow−$2.12M−$3.64M−$7.83M−$9.06M−$15.6M−$14.2M−$18.1M−$17.1M$27.0M−$12.5M

From Fennec Pharmaceuticals Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

About Fennec Pharmaceuticals Inc

Headquarters
Research Triangle Park, North Carolina From SEC filings, Oct 2026

Recent News (2)

More Health Care stocks

Browse all companies →